365 related articles for article (PubMed ID: 24778403)
1. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
Ponader S; Burger JA
J Clin Oncol; 2014 Jun; 32(17):1830-9. PubMed ID: 24778403
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
4. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.
Vargas L; Hamasy A; Nore BF; Smith CI
Scand J Immunol; 2013 Aug; 78(2):130-9. PubMed ID: 23672610
[TBL] [Abstract][Full Text] [Related]
6. Targeting Bruton's tyrosine kinase in B cell malignancies.
Hendriks RW; Yuvaraj S; Kil LP
Nat Rev Cancer; 2014 Apr; 14(4):219-32. PubMed ID: 24658273
[TBL] [Abstract][Full Text] [Related]
7. Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia.
Ramalho VD; Oliveira Júnior EB; Tani SM; Roxo Júnior P; Vilela MM
Braz J Med Biol Res; 2010 Sep; 43(9):910-3. PubMed ID: 20721470
[TBL] [Abstract][Full Text] [Related]
8. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
9. BTK Signaling in B Cell Differentiation and Autoimmunity.
Corneth OBJ; Klein Wolterink RGJ; Hendriks RW
Curr Top Microbiol Immunol; 2016; 393():67-105. PubMed ID: 26341110
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
Lucas F; Woyach JA
Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase--an integral protein of B cell development that also has an essential role in the innate immune system.
López-Herrera G; Vargas-Hernández A; González-Serrano ME; Berrón-Ruiz L; Rodríguez-Alba JC; Espinosa-Rosales F; Santos-Argumedo L
J Leukoc Biol; 2014 Feb; 95(2):243-50. PubMed ID: 24249742
[TBL] [Abstract][Full Text] [Related]
12. The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils.
Broides A; Hadad N; Levy J; Levy R
J Clin Immunol; 2014 Jul; 34(5):555-60. PubMed ID: 24771458
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Alinari L; Quinion C; Blum KA
Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
[TBL] [Abstract][Full Text] [Related]
14. Potential application of gene therapy to X-linked agammaglobulinemia.
Moreau T; Calmels B; Barlogis V; Michel G; Tonnelle C; Chabannon C
Curr Gene Ther; 2007 Aug; 7(4):284-94. PubMed ID: 17969561
[TBL] [Abstract][Full Text] [Related]
15. Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
Göckeritz E; Vondey V; Guastafierro A; Pizevska M; Hassenrück F; Neumann L; Hallek M; Krause G
Br J Haematol; 2017 Sep; 178(6):949-953. PubMed ID: 28573668
[TBL] [Abstract][Full Text] [Related]
16. Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.
Brunner C; Kreth HW; Ochs HD; Schuster V
J Clin Immunol; 2002 Jul; 22(4):244-51. PubMed ID: 12148599
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
18. Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan.
Hashimoto S; Tsukada S; Matsushita M; Miyawaki T; Niida Y; Yachie A; Kobayashi S; Iwata T; Hayakawa H; Matsuoka H; Tsuge I; Yamadori T; Kunikata T; Arai S; Yoshizaki K; Taniguchi N; Kishimoto T
Blood; 1996 Jul; 88(2):561-73. PubMed ID: 8695804
[TBL] [Abstract][Full Text] [Related]
19. Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model.
Pérez de Diego R; López-Granados E; Rivera J; Ferreira A; Fontán G; Bravo J; García Rodríguez MC; Bolland S
Clin Exp Immunol; 2008 Apr; 152(1):33-8. PubMed ID: 18241233
[TBL] [Abstract][Full Text] [Related]
20. Debilitating progressive encephalitis in a patient with BTK deficiency.
Mohammadzadeh I; Yeganeh M; Khaledi M; Salehiomran MR; Aghamohammadi A; Rezaei N
Acta Microbiol Immunol Hung; 2012 Sep; 59(3):335-42. PubMed ID: 22982637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
